All patients deserve access to the right testing & treatment at the right time

 From Testing to Targeted Treatment Program (FT3) is a non-profit multi-stakeholder collaborative program that aims to unify, accelerate and build on existing efforts, to make precision medicine a reality for all patients who could benefit from it. Co-led by patients, FT3 is strongly focused on patient needs and experiences.

All patients deserve access to the right testing & treatment at the right time

From Testing to Targeted Treatment Program (FT3) is a collaborative program to make precision medicine a reality for all patients who could benefit from it.

Program highlights

Could genetic testing unlock treatments for Cancer of Unknown Primary?

World CUP Week: Researchers are screening hundreds of tumour genes in search of drug targets that could open the door to more personalised cancer care

Program update – September 2021

Here is an update on latest developments in FT3 including ideas to get involved and engage your network.

2020 From Testing to Targeted Treatment Annual Report

Moving from incubation to a shared operational program

About us

Our motivation

All patients deserve access to the right testing & treatment at the right time. While Precision Medicine (PM) can transform lives, its potential benefits have not yet been fully realized.

Our ambition

Our goal is to improve access to precision medicine for all patients who could benefit from it, by generating better evidence, creating awareness and building the conditions for better access, starting with testing and cancer.

The partnership

We are an independent, nonprofit, global and multistakeholder consortium, building solutions with patients, for patients. Its members and community include individual patients, patient organizations, pharmaceutical & diagnostics companies, healthcare professionals and medical societies, payers, HTA bodies and regulators.

Keep up to date with developments from the precision medicine ecosystem

We don’t spam. Just key info at the right time.

Founding members